Structure Therapeutics (GPCR) Competitors

ADMA Biologics (NASDAQ:ADMA) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Does the media prefer ADMA or GPCR?

In the previous week, ADMA Biologics and ADMA Biologics both had 8 articles in the media. Structure Therapeutics' average media sentiment score of 1.08 beat ADMA Biologics' score of 0.78 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Structure Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ADMA or GPCR more profitable?

ADMA Biologics has a net margin of 17.80% compared to Structure Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	17.80%	53.20%	26.07%
Structure Therapeutics	N/A	-16.37%	-15.68%

Which has preferable earnings and valuation, ADMA or GPCR?

ADMA Biologics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$459.38M	10.84	-$28.24M	$0.85	24.54
Structure Therapeutics	N/A	N/A	-$89.62M	-$0.87	-25.09

Do insiders and institutionals have more ownership in ADMA or GPCR?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer ADMA or GPCR?

ADMA Biologics received 381 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 87.18% of users gave Structure Therapeutics an outperform vote while only 72.05% of users gave ADMA Biologics an outperform vote.

Company	Underperform	Outperform
ADMA Biologics	Outperform Votes 415 72.05%	Underperform Votes 161 27.95%
Structure Therapeutics	Outperform Votes 34 87.18%	Underperform Votes 5 12.82%

Do analysts rate ADMA or GPCR?

ADMA Biologics currently has a consensus price target of $24.25, indicating a potential upside of 16.25%. Structure Therapeutics has a consensus price target of $76.50, indicating a potential upside of 250.44%. Given Structure Therapeutics' higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Structure Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, ADMA or GPCR?

ADMA Biologics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.87, indicating that its share price is 287% less volatile than the S&P 500.

Summary

ADMA Biologics beats Structure Therapeutics on 11 of the 17 factors compared between the two stocks.